Streetwise Management Q&As


Rik Deitsch

OTC Strategy Supports Cobra Venom Pipeline in Asia and North America: Nutra Pharma's Rik Deitsch
Source: Gail Dutton of The Life Sciences Report  (10/21/15)
A strategy of over-the-counter sales helps derisk Nutra Pharma Corp. as it advances a therapeutic pipeline based on cobra toxin. In this interview with The Life Sciences Report, CEO Rik Deitsch elaborates how he plans to grow the company through distribution of Nutra Pharma's pain medications in India, China, Canada and the U.S., and how therapies based on the toxin can address a variety of autoimmune diseases. More >


Ross Macdonald

Delivering the Triple Whammy that Makes Stem Cell Therapies Commercially Viable: Cynata Therapeutics' Ross Macdonald
Source: Gail Dutton of The Life Sciences Report  (10/14/15)
Stem cell therapies have been slowed by high production costs, batch-to-batch variability and limited seed material. Ross Macdonald, CEO of Cynata Therapeutics, tells The Life Sciences Report how his company's innovative manufacturing methods can generate robust, consistent and inexpensive stem cells, and how this technology is likely to accelerate the commercialization of stem cell therapies worldwide. More >


Joseph Wagner Charles Wiseman Saeid Babaei

Breakthrough Potential: BriaCell Therapeutics Takes Its Cancer Vaccine to the Next Level
Source: Gail Dutton of The Life Sciences Report  (9/30/15)
Immuno-oncology has the potential to not only transform medicine, but also to become a multibillion-dollar market for a drug developer with the right team and the right compound. In this interview with The Life Sciences Report, BriaCell Therapeutics Corp. executives Joseph Wagner, Charles Wiseman and Saeid Babaei describe their company's new therapeutic, which has generated stunning results in early trials, making "breakthrough" designation by the FDA a realistic possibility. More >


Robert Erwin

The Promise of Plants in Pharmaceutical Production: iBio's Robert Erwin
Source: Gail Dutton of The Life Sciences Report  (9/9/15)
The growing need for recombinant proteins for vaccines and therapeutics is causing the biotech industry to look beyond vat fermentation and cell cultures for protein expression systems that, like iBio Inc.'s iBioLaunch technology, can increase yields quickly, safely and inexpensively. In this interview with The Life Sciences Report, iBio's President Robert L. (Bob) Erwin describes the iBioLaunch technology and what it offers to drug developers and investors. More >


Donald McCaffrey

Disrupting Treatment of Cardiovascular Disease with Epigenetics: Resverlogix CEO Donald McCaffrey
Source: Gail Dutton of The Life Sciences Report  (8/26/15)
The evidence is mounting: Resverlogix Corp.'s first-in-class, epigenetics-based drug candidate has demonstrated its ability to significantly reduce major adverse cardiac events (MACE)—death, heart attacks, strokes and heart failure, particularly in diabetic patients—in three consecutive clinical trials. That, company President and CEO Donald McCaffrey tells The Life Sciences Report, is why RVX-208 will likely be a blockbuster. More >


Gil Van Bokkelen

The Next Phase for MultiStem: Athersys' Gil Van Bokkelen
Source: George S. Mack of The Life Sciences Report   (8/12/15)
Regenerative medicine is surging toward the mainstream, and Athersys Inc. is riding the crest. Potential safety concerns surrounding cell therapies have been largely addressed, and now the efficacy of the company's MultiStem platform in several massive markets, including stroke, heart attack and acute pulmonary disease, are ready to be tested. As the company advances its portfolio of programs, Chairman and CEO Gil Van Bokkelen tells The Life Sciences Report about the promise that MultiStem holds for both patients and investors. More >


Joseph Patti

Biota Pharmaceuticals' Direct-Acting Antivirals Target the Root Cause of Viral Conditions
Source: Gail Dutton of The Life Sciences Report  (7/14/15)
Direct-acting antiviral therapies are poised to become a major disruptive technology in treatment for viruses, including human rhinovirus and human papillomavirus. Dr. Joseph M. Patti, CEO of Biota Pharmaceuticals Inc., tells The Life Sciences Report about the novel antiviral therapies in his company's pipeline that address the cause of viral conditions, rather than merely the symptoms. More >


Ron Najafi

A Clear Vision for a Turnaround: Ron Najafi of NovaBay Pharmaceuticals
Source: George S. Mack of The Life Sciences Report  (6/24/15)
What a difference just nine months can make. NovaBay Pharmaceuticals Inc. has a materially derisked business strategy with new products coming rapidly to market, big-time distribution partners in place and new shareholders embracing the stock following a drug trial disappointment in mid-August 2014. In this interview with The Life Sciences Report, company founder, President and CEO Dr. Ramin "Ron" Najafi talks about the turnaround and how he is steering the product portfolio toward a hockey-stick sales growth curve. More >


Geert Cauwenbergh

It's All in the Delivery: How RXi Pharmaceuticals' Innovative Platform Will Transform Medicine
Source: BTV/The Life Sciences Report  (5/29/15)
Inhibition—developing therapies that can suppress certain disease mechanisms—is a major thrust in modern biotech. With its unique RNA interference delivery platform, spun out from the mind of a Nobel laureate, CEO Dr. Geert Cauwenbergh tells The Life Sciences Report about the transformational treatments RXi Pharmaceuticals Corporation has in the pipeline, therapies that can both enrich lives and investors' portfolios. More >


James Sapirstein

ContraVir Pharmaceuticals Brandishes a New Weapon in Biotech's Antiviral Wars
Source: Peter Byrne of The Life Sciences Report  (5/27/15)
Nobody understands the ins and outs of the antivirals better than the CEO of ContraVir Pharmaceuticals, and James Sapirstein unfolds the backstory behind the creation of his newest venture in this interview with The Life Sciences Report. Millions of patients around the globe await the unveiling of the company's emerging pipeline products targeting the viruses that cause shingles and hepatitis B—products that also promise opportunity to biotech investors. More >


Tony Fiorino

BrainStorm Cell Therapeutics Tackles Neurodegenerative Disease with Super Cells
Source: Peter Byrne of The Life Sciences Report  (5/20/15)
An Israeli biotech is hard at work on a new treatment for neurodegenerative disease that holds promise in a variety of devastating diseases and enjoys fast-track and orphan drug status in its lead indication, amyotrophic lateral sclerosis (ALS). Dr. Tony Fiorino, the U.S.-based CEO of BrainStorm Cell Therapeutics Inc., tells The Life Sciences Report how his company is winning over American investors with a revolutionary, university lab-backed cell therapy. More >


David Luci

Dipexium Pairs the African Clawed Frog and Business Savvy for an Antibiotic Wound Care Solution
Source: Peter Byrne of The Life Sciences Report  (5/7/15)
David Luci, CEO of Dipexium Pharmaceuticals Inc., tells The Life Sciences Report why he believes his firm's new skin-healing product may soon dominate a broad international market niche. Investors take note: Not only is the company's product promising, its top management also spearheaded a successful initial public offering—a combo that could prove a potent addition to a biotech portfolio. More >


Lawrence Mayer Scott Jackson

Celator's New Drug Combo Will Revolutionize AML Standard of Care: Scott Jackson and Lawrence Mayer
Source: Peter Byrne of The Life Sciences Report  (4/22/15)
Celator Pharmaceuticals Inc.'s remarkable drug combination strategy has produced a cancer-fighting duo endowed with a coveted fast-track designation. Scott Jackson, the company's CEO, and Lawrence Mayer, president, chief scientific officer and founder, tell The Life Sciences Report about what sets Celator apart, and reveal profit-generating milestones that investors should keep on their scopes. More >


Alexander Zukiwski

Arno Therapeutics Seeks to Inhibit Cancer and Enhance Portfolios: CEO Alexander Zukiwski
Source: Daniel Levy, The Life Sciences Report  (4/8/15)
Cancers are generally treated by destruction of cancer cells. Infectious diseases are generally treated by destruction of invading pathogens. If infected host cells are viewed as viable biological targets, new paradigms for development of anti-infective agents become apparent. In this interview with The Life Sciences Report, Alexander Zukiwski MD, CEO and CMO of Arno Therapeutics Inc., describes how onapristone and AR-42 for cancers, and AR-12 as an anti-infective agent, are positioned to move through clinical trials and boost investors' portfolios. More >


Christopher Schaber

Soligenix Takes the Fast Track to Beat Inflammation, Cancer and Bio-Threats: Dr. Christopher Schaber
Source: Daniel Levy, The Life Sciences Report  (4/8/15)
Orphan diseases associated with inflammation present excellent development opportunities for small biopharmaceutical companies and their investors. Additionally, inflammatory conditions can result from treatment with cancer therapeutics. The crossover between inflammation and oncology, coupled with vaccine programs of high strategic value, have allowed Soligenix Inc. to build a significant pipeline with substantial revenue potential. In this interview with The Life Sciences Report, Dr. Christopher J. Schaber, company President and CEO, outlines development programs targeting pediatric Crohn's disease, GI acute radiation syndrome, a rare lymphoma and the threat of ricin. More >


Dan Swisher, Jr.

How Sunesis Pharmaceuticals Can Inhibit Cancer While Enhancing Investments: CEO Daniel Swisher
Source: Daniel Levy, The Life Sciences Report  (4/2/15)
Cancers are among today's most significant unmet medical needs. Take, for example, acute myelogenous leukemia: No new therapeutics have hit the marketplace in more than forty years. In this interview with The Life Sciences Report, Daniel N. Swisher Jr., president and CEO of Sunesis Pharmaceuticals Inc., describes how his company is making clinical progress toward developing a new treatment for this devastating disease, and how the broad Sunesis kinase inhibitor portfolio provides additional firepower against other cancers. With a number of share-moving catalysts on the horizon, Sunesis expects to hit the mark both for patients and investors. More >


Pnina Fishman

One Target with Multiple Shots on Goal: Can-Fite BioPharma CEO Pnina Fishman
  (3/4/15)
The target is a single receptor found only on abnormal cells—cancer cells and cells responsible for inflammatory diseases such as psoriasis. The weapon is a platform technology developed by Can-Fite BioPharma Ltd. under the guidance of Scientific Founder and CEO Pnina Fishman and her team. The company is developing an arsenal of therapies approaching the final stages of clinical trials, and in this interview with The Life Sciences Report, Fishman describes the catalysts and candidates that make Can-Fite a strong bet for investors. More >


Geert Kersten

CEL-SCI Corp.'s Novel Immunotherapies Set Sights on Cancer, Autoimmune Disorders and Infectious Diseases
Source: Dan Levy of The Life Sciences Report  (2/19/15)
Control and manipulation of the immune system is the underlying basis behind vaccinations in the fight against dangerous infectious diseases, but using immunotherapies to treat cancers and autoimmune disorders has been limited. That paradigm is changing, and CEL-SCI Corp. is among the companies poised to bring immunotherapy into these disease spaces. In this interview with The Life Sciences Report, Geert Kersten, CEL-SCI's CEO, describes how his company's Multikine and L.E.A.P.S. platforms can be deployed, and how investors can turn an immunotherapeutic win into profit. More >


The Diabetes Economy: Miraculins Scouts for Worldwide Markets
Source: Taylor Thoen, BTV/The Life Sciences Report   (2/4/15)
While other diseases catch headlines and media attention, diabetes has crept quietly into a full-blown, worldwide pandemic. With the Scout DS®, Winnipeg-based Miraculins Inc. is on the leading edge of medical innovation with the world's first noninvasive retail screening test for diabetes. In this interview with The Life Sciences Report, Miraculins President and CEO Christopher Moreau explains how the company is poised to expand into multiple markets to meet a desperate need for diabetes screening in North America and around the world. More >


Harry Fleming

The Outpatient Surgery Business Rains Cash: Nobilis Health's Harry Fleming
Source: Peter Byrne of The Life Sciences Report  (1/22/15)
Nobilis Health Corp. has invented a genuine recipe for success: Provide outpatient surgical services with high profit margins and saturate a local consumer health market with advertising. In this interview with The Life Sciences Report, Nobilis' president Harry Fleming explains exactly how his booming firm's business model works—and why investors should take note of the new kid on the block. More >


Taking Multiple Shots on the Cancer Treatment Goal: Rexahn's Peter Suzdak
Source: George S. Mack of The Life Sciences Report  (11/28/14)
Rexahn Pharmaceuticals Inc.'s cancer-fighting drug development platform is built on a theme that focuses on targets exclusive to tumor cells—the ultimate strategy in the silver-bullet theory of dealing with disease because it can increase efficacy while reducing off-target effects, including heart and liver toxicity. Moreover, lower toxicity enables higher drug doses, which could enhance the desired therapeutic effects. In this interview with The Life Sciences Report, Rexahn CEO Peter D. Suzdak, Ph.D. talks about his company's clinical-stage drug candidates, and links their mechanisms of action to the ultimate value proposition for owning company shares. More >


R. Lee Buckler

R. Lee Buckler: How RepliCel Is Harnessing the Awesome Power of Cell Therapy
Source: George S. Mack of The Life Sciences Report  (11/6/14)
Regenerative medicine and cell therapies hold possibilities for achieving near miracles in a multitude of indications, from life-saving treatments to aesthetic applications. RepliCel Life Sciences Inc. (RP:TSX.V; REPCF:OTCQB) is tackling a mix of medical and cosmetic issues that include hair regeneration, repair of painful and debilitating tendon injuries and rejuvenation of damaged skin. In this interview with The Life Sciences Report, R. Lee Buckler, the company's new vice president of business and corporate development, discusses his firm's innovative technology platform and the upcoming milestones that could affect its shares. More >


J. Joseph Kim

The Game-Changing Potential of DNA Vaccines: Inovio's Dr. Joseph Kim
Source: George S. Mack of The Life Sciences Report  (10/29/14)
Since Edward Jenner's development of the smallpox vaccine in the late 1790s, humankind has enjoyed the benefit of immunization, which has saved many millions of lives. Today, Inovio Pharmaceuticals Inc. (INO:NASDAQ) is in the forefront of developing DNA vaccines, inserting engineered genes into cellular machinery to synthesize proteins that, in turn, generate antibodies that fight disease. An additional benefit is a powerful T-cell response, which harnesses the patient's own capacity to fight infections and cancers. If pivotal studies read out favorably, DNA immunization could prove a true game changer in healthcare. In this interview with The Life Sciences Report, Inovio President and CEO J. Joseph Kim discusses his company's platform technology, which addresses both therapeutic and preventive methods of fighting disease. More >


Steven Davidson

Follow the Baby Boom to Profits: Agility Health's Steven Davidson
Source: Peter Byrne of The Life Sciences Report  (10/21/14)
In recent years, entrepreneurial therapists have comprised the fast-growing sector in outpatient physical therapy. But companies like Agility Health are beginning to seize acquisition opportunities and market share in this growing sector. Steven Davidson, CEO of Agility Health Inc., tells The Life Sciences Report how his company is innovating in the physical therapy space, improving patient care and clients' bottom lines through its management expertise and proprietary software, AgileRPM. With baby boomers aging and the Affordable Care Act increasing access to services, physical therapy just might be the safe haven sector to shield your portfolio from macroeconomic uncertainty. More >


Erez Raphael

Dial In on Diabetes Solutions with LabStyle Innovations Corp.'s Dario
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (7/17/14)
Having a chronic disease like diabetes engenders a sense of isolation that hasn't been adequately addressed by technology until now. With Dario, LabStyle Innovations Corp. has created a device that not only provides vital medical information to a diabetic patient in real time, but also connects that patient to a community of care providers, family and online resources. In this interview with The Life Sciences Report, LabStyle President and CEO Erez Raphael describes how the Dario software platform could provide sufferers of other chronic diseases with the benefits of real-time data and community as well. More >


Showing Results: 26 to 50 of 55 Prev Next